Shuttle Pharma signs letter of intent to acquire AI firm Molecule.ai
PositiveFinancial Markets

Shuttle Pharma has announced a letter of intent to acquire the AI firm Molecule.ai, marking a significant step in enhancing its technological capabilities. This acquisition is expected to bolster Shuttle Pharma's research and development efforts, allowing for more innovative solutions in the pharmaceutical industry. The integration of AI technology could lead to improved drug discovery processes, ultimately benefiting patients and the healthcare sector.
— Curated by the World Pulse Now AI Editorial System